Pete,
Thanks for the release:
----------------------------------------------------------------------------------------------------------
Immune Network Research Ltd.
>> IMM VSE
>>
>> December 2, 1996
>>
>> Report To Shareholders Nine Months Ended Sept 30, 1996 Financial
>> Statements Available from the Company
>>
>> IMMUNE NETWORK RESEARCH LTD. ("IMM-V")
>>
>> - Report To Shareholders Nine Months Ended Sept 30, 1996 - Financial
>> Statements Available from the Company
>>
>> Immune Network Research Ltd. announced following the annual general
>> meeting held on October 31, the Board welcomed Dr. George L.
>> Spitalny as President and a director and has set priorities to
>> complete the work on CTB-1 and to seek new technologies to augment
>> the on-going monoclonal antibody for reagent and research into HIV.
>> The monoclonal antibody program is continuing and our anti-HIV
>> monoclonal antibodies are distributed by SeroTec Ltd under a non
>> exclusive contract. The Company has received very modest royalties
>> from the sales of its reagent monoclonals to date. A report and
>> recommendations are expected shortly on the work carried out using
>> the CTB-1 monoclonal antibody of the University of Kentucky and
>> Harvard laboratories where three rhesus macaques were infected with
>> a recombinant form of Hiv earlier this year. These animals received
>> four intravenous injections of 5 mg of CTB-1 over a 2 week period.
>> Significantly, no adverse reactions to the injections were observed
>> over three months of follow-up. The full analysis of the data and
>> recommendations are expected for the next steps in "in vivo"
>> research on this potentially important antibody. In addition to the
>> work on monoclonal antibodies, negotiations are on-going with
>> respect to the acquisition of related technologies. The theoretical
>> work on the EHT program has been postponed in order for the Company
>> to focus on research with improved near term commercial potential.
>> The developer of the EHT program, Dr. Geoffrey W. Hoffman, has left
>> the Company. The Board of Directors terminated at the request of the
>> Vancouver Stock Exchange, the announced due diligence and proposed
>> merger with a United States based company and shares were reinstated
>> for trading. On other corporate matters, the warrants associated
>> with the IPO financing expired without exercise and the expiry date
>> of warrants which are exercisable to purchase up to 183,333 shares
>> at $0.60 per share, issued as a result of a private placement
>> financing in 1995, were extended to June 7, 1997, in accordance with
>> Vancouver Stock Exchange policy. The Genesis Group continues to
>> provide the Company with investor relations services under a
>> previously disclosed contract. Members of senior management also
>> assist with investor relations. The Company looks forward to an
>> improved research program and developments from its research and
>> technology acquisition program.
>>
>> TEL: (604) 689-3923 Dr. George L. Spitalny, President FAX: (604)
>> 684-5854
>>
>> ________
>>
>> (c) Corporate Dissemination Services Inc. All rights reserved.
>>
>> Tel:(604) 689-1101 Fax:(604) 689-1106
>>
>> RapidFAX (tm) - To get the NEWS as it happens, call (604) 689-3041.
>>
>> This release processed by Canstock at 12:38:47 Pacific Time
>> --------------------------------------------------------------------
>> [Toolbar]
>> |Front Page| |Portfolio| |Charts| |Quotes| |News| |Market Review|
>> |Download Data|
>> |Contact Us| |Search| |Profiles| |News Archive| |Insider Reports|
>> |Help|
>> --------------------------------------------------------------------
>> The information included in this document was provided by Immune
>> Network Research Ltd. and the Canadian Stock Market Reporter assumes
>> no responsibility for its accuracy.
>> c1996 Canadian Stock Market Reporter
------------------------------------------------------------------------------------------->
>
>
> |
